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A bacterial route for folic acid
supplementation
Claire Maynard1, Ian Cummins1, Jacalyn Green2 and David Weinkove1,3*
Abstract
Background: To prevent folate deficiencies, many countries supplement various foodstuffs with folic acid. This
compound is a synthetic oxidised folate that differs from naturally occurring reduced folates in its metabolism and
uptake. Notably, safety reviews of folic acid supplementation have not considered interactions with gut bacteria.
Here, we use the Caenorhabditis elegans – Escherichia coli animal– microbe model to examine a possible bacterial
route for folic acid uptake. It has been assumed that supplements are taken up directly by the worm, especially
because E. coli is unable to take up folates. However, E. coli, like many other bacteria, can transport the folate
breakdown product, para-aminobenzoate-glutamate (PABA-glu), via AbgT and use it for bacterial folate synthesis.
This pathway may impact host health because inhibition of bacterial folate synthesis increases C. elegans lifespan.
Results: Folic acid supplementation was found to rescue a C. elegans developmental folate-deficient mutant;
however, a much higher concentration was required compared to folinic acid, a reduced folate. Unlike folinic acid,
the effectiveness of folic acid supplementation was dependent on the E. coli gene, abgT, suggesting a bacterial
route with PABA-glu uptake by E. coli as a first step. Surprisingly, we found up to 4% PABA-glu in folic acid
preparations, including in a commercial supplement. Via breakdown to PABA-glu, folic acid increases E. coli folate
synthesis. This pathway restores folate synthesis in a bacterial mutant defective in PABA synthesis, reversing the
ability of this mutant to increase C. elegans lifespan.
Conclusions: Folic acid supplementation in C. elegans occurs chiefly indirectly via bacterial uptake of breakdown
products via E. coli AbgT, and can impact C. elegans development and longevity. Examining how folic acid
supplementation affects bacterial folate synthesis in the human gut may help us to better understand the safety of
folic acid supplementation.
Background
The folate cycle involves a series of essential biosynthetic
reactions known as one-carbon metabolism [1]. Folates
are a family of molecules composed of three common
elements: a central aromatic core derived from
para-amino benzoic acid (PABA), a pterin ring that can
be modified and a chain of one or more glutamates [2].
At each step of the folate cycle, an enzyme mediates a
modification of the pterin ring of the bound folate,
allowing the transfer of a chemical group containing one
carbon atom (methyl, formyl, etc.) to or from the com-
pound being synthesised [1]. This cofactor role results in
folate molecules being recycled and thus they are only
required in very small amounts.
Animals cannot synthesise folates and must acquire
them from their diet or gut microbes. When these
sources are insufficient, folate deficiency can lead to
neural tube defects during human embryonic develop-
ment [1]. The rate of these defects can be lowered by
preconception supplementation with folic acid, an oxi-
dised form of folate not found in nature. Mandatory
fortification of flour with folic acid has successfully de-
creased the incidence of birth defects in many countries,
including the US and Canada [3]. However, there are
concerns that folic acid supplementation may have ad-
verse effects on health, especially in older people [4–7],
and there are many unknowns about the efficacy of
uptake and biological utilisation of folic acid [8]. Despite
these uncertainties, recent reviews of the evidence by
* Correspondence: david.weinkove@durham.ac.uk
1Department of Biosciences, Durham University, Stockton Road, Durham DH1
3LE, UK
3Biophysical Sciences Institute, Durham University, South Road, Durham DH1
3LE, UK
Full list of author information is available at the end of the article
© Weinkove et al. 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Maynard et al. BMC Biology  (2018) 16:67 
https://doi.org/10.1186/s12915-018-0534-3
experts acting for government public health bodies have
concluded that the risks are minimal and have recom-
mended the fortification of flour or other food products
as a beneficial intervention [3, 9, 10].
None of the above safety reviews mention potential
interactions with gut bacteria. Bacteria also require
folates for biosynthesis. Many make their own folates,
but folates can also be taken up from the environment.
Little is known about how bacterial folate biochemistry
affects the host. Inhibiting Escherichia coli folate biosyn-
thesis, either by treatment with the drug sulfamethoxa-
zole (SMX) or mutation of the PABA synthesis pathway
(e.g., a pabA or pabB mutant), extends the lifespan of
the nematode Caenorhabditis elegans that feeds on it
[11–13]. While these interventions decrease the folate
levels in both E. coli and C. elegans, there remains suffi-
cient folate available to support normal growth of both
organisms [12]. We have suggested that bacterial folate,
at higher levels than need for growth, enables a bacterial
activity that shortens the life of C. elegans and is inde-
pendent of the folate status of C. elegans [13]. Thus, the
folate status of gut bacteria may be important for host
health.
To understand the interaction between bacterial and
animal folates, we have developed a C. elegans folate
deficiency model, a mutant in gcp-2.1 and homologue of
human GCPII, which is required for uptake of dietary
polyglutamated folates [13]. The only way we have
found of decreasing C. elegans folate enough to slow
growth is by raising the C. elegans gcp-2.1 mutant on
SMX-treated E. coli. Under these conditions, worms
show delayed development and infertility [13]. This
phenotype can be prevented with 1–10 μM folinic acid,
a reduced folate which can be absorbed directly by C.
elegans, demonstrating that this defect is due to folate
deficiency. In contrast, prevention with folic acid re-
quires much higher concentrations (100 μM) [13]. We
also discovered that, at high concentrations, folic acid
can partially reverse the lifespan increase caused by
inhibiting E. coli folate synthesis [12]. A possible ex-
planation for this result might be the restoration of E.
coli folate levels, but that would be a surprising con-
clusion because E. coli does not possess a folate
transporter [14, 15]. However, it is known that E. coli
can take up the folic acid breakdown product
PABA-glu through the transporter AbgT and catabo-
lise it to PABA [16]. PABA can also diffuse across E.
coli membranes. Increases in bacterial PABA levels
from either source can be used to synthesise folate.
In this study, we examine whether these routes might
explain the lifespan effects of folic acid.
Here, we use a system in which the external media,
microbe and animal can be carefully controlled, to
ask whether folic acid is taken up directly by C. ele-
gans or uptake of folic acid breakdown products by
E. coli represents an important alternative route
(Fig. 1). We show that the prevention of developmen-
tal defects of the C. elegans folate deficiency model
by adding folic acid depends on the E. coli AbgT
transporter, demonstrating that bacterial uptake is the
major route of supplementation. Consistent with this
route, we show folic acid increases E. coli folate
levels through a pathway that involves uptake of
PABA-glu by the AbgT transporter and that
PABA-glu is present in folic acid preparations. We
also find that this pathway can reverse the lifespan
increase caused by inhibiting E. coli folate synthesis.
In summary, we have uncovered an unappreciated
breakdown product in folic acid supplements and a
bacterial route of uptake that can increase host folate
Fig. 1 Schematic representing possible C. elegans and bacterial-dependent routes of folic acid supplementation. C. elegans depends on E. coli for
folate. E. coli synthesizes reduced tetrahydrofolates de novo via the PABA pathway. The synthetic folate supplement, folic acid, is oxidised and
must be enzymatically reduced into a tetrahydrofolate before it is bioavailable. E. coli cannot take up intact folic acid, but it can take up the
breakdown product, PABA-glu. The inner membrane transporter AbgT transports PABA-glu, where it is cleaved intracellularly by a heterodimeric
complex to generate PABA. Free PABA is then used to generate tetrahydrofolates. It is not clear whether this bacterial pathway is significant in
the supplementation of an animal by folic acid
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levels indirectly but might also increase bacterial toxicity,
accelerating ageing.
Results
E. coli is required for folic acid supplementation to
prevent a C. elegans folate deficiency
In order to examine if E. coli is required for folic acid to
prevent developmental defects in our C. elegans folate
deficiency model, we tested whether the E. coli abgT
genotype influenced the outcome of supplementation.
Our folate deficiency model [13] is based on the measur-
able growth defect of the C. elegans gcp-2.1(ok1004)
mutant during larval development, when it is grown on
OP50 E. coli treated with 128 μg/mL SMX (Fig. 2a). In
this study, we found a similar growth phenotype (Fig. 2a)
when we grew this C. elegans mutant on an E. coli ΔpabA
mutant (which cannot make its own folate because it
cannot make the folate precursor PABA). To eliminate ex-
ogenous PABA, we grew the bacteria on a defined media
(DM) containing only amino acids, salts, cholesterol and
trace metals [13]. Mutation of E. coli abgT alone did not in-
fluence the growth of the C. elegans gcp-2.1 mutant (Fig.
2a), because de novo folate synthesis is unaffected by the
ΔabgT mutant. To examine the role of AbgT in the ab-
sence of endogenous folate synthesis, an E. coli ΔabgT
ΔpabA double mutant strain was constructed. Develop-
mental growth of C. elegans gcp-2.1 mutants on the ΔabgT
ΔpabA E. coli was delayed just as it was on the ΔpabA mu-
tant. In response to folic acid supplementation over a
100-fold concentration range, a dose-dependent increase in
body length was observed for gcp-2.1 mutants on the E. coli
ΔpabA mutant, which was not observed on the ΔabgT
ΔpabA mutant (Fig. 2bi, asterisks indicate significant differ-
ence between ΔpabA and ΔabgT ΔpabA). In contrast to
a
bi bii
ci cii
Fig. 2 Folic acid supplementation prevents developmental growth defect of a C. elegans folate deficiency model via an E. coli abgT-dependent
route. Body length of WT and gcp-2.1 mutant C. elegans at L4 developmental stage raised on DM agar plates seeded with (a) WT E. coli (control),
WT E. coli treated with 128 μg/mL SMX, ΔpabA mutant, and ΔabgT mutant, (b) ΔpabA mutant, ΔabgT ΔpabA double mutant, ΔpabA (abgT OE),
and supplemented with increasing concentrations of folic and (c) folinic acid. Error bars represent standard deviation of C. elegans body length,
where n≥ 40. Asterisks (*) indicate test statistic of unpaired non-parametric Mann–Whitney t tests, where ****p < 0.0001, ***p < 0.001, **p < 0.01,
*p < 0.05. By two-way ANOVA analyses, we find that there is a significant interaction effect of strain type (F = 102.67, p < 0.0001) and folic acid
concentration (F = 123.55, p < 0.0001) on C. elegans gcp-2.1 body length. Over-expression of abgT is conferred by transformation with a high copy
number plasmid, pJ128. ΔpabA and ΔabgT ΔpabA strains are transformed with the empty vector, pUC19
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the 200 μM folic acid required to completely rescue growth
of the gcp-2.1 mutant worms on E. coli ΔpabA and
ΔabgT ΔpabA, only 1 μM folinic acid was required,
and supplementation was independent of E. coli geno-
type (Fig. 2bii), consistent with a direct route to the worm
for folinic acid.
Overexpression of abgT in the E. coli ΔpabA mutant
(ΔpabA (abgT OE)) increased gcp-2.1 mutant body
length at lower concentrations of folic acid, with a
complete rescue achieved at 100 μM folic acid (Fig. 2ci).
Consistent with the previous experiment, folinic acid res-
cued gcp-2.1 mutant growth at a 100-fold lower concen-
tration and independently of abgT expression (Fig. 2cii).
Analysing the experiment by two-way ANOVA, we find
that there is a significant interaction effect of abgT geno-
type (F = 102.67, p < 0.0001) and folic acid concentration
(F = 123.55, p < 0.0001) on C. elegans gcp-2.1 body length
(Fig. 2ci). These results are consistent with folinic acid be-
ing taken up directly by the worm [17], and the major
route of folic acid uptake requiring E. coli and the E. coli
AbgT transporter.
Folic acid supports growth of E. coli pabA mutants via
abgT-dependent uptake of PABA-glu
As AbgT is known to transport the folate breakdown
product PABA-glu, the results above suggest that
PABA-glu is available to E. coli following folic acid sup-
plementation. To test this assertion, we conducted
growth experiments using the E. coli ΔpabA mutant
under conditions in which there was insufficient exogen-
ous PABA available to support growth, namely growth
on DM agar plates when seeded after several generations
of growth in liquid DM. We assessed how the growth of
the ΔpabA, ΔabgT ΔpabA and ΔpabA (abgT OE) strains
could be restored with folic acid, PABA-glu or PABA
when added to the media. We found that the growth
restored by folic acid or PABA-glu depended on abgT
expression; 10 μM folic acid rescued the growth of the
ΔpabA mutant, whereas 100 μM was needed to achieve
an equivalent rescue in the ΔabgT ΔpabA double mu-
tant (Fig. 3). In the presence of 10 μM folic acid, growth
of the ΔpabA strain over-expressing AbgT was greater
than that of the ΔpabA mutant alone. Supplementation
by PABA-glu had a similar effect to folic acid but at a
10-fold lower concentration (Fig. 3), consistent with re-
sults of experiments in liquid at 37 °C [16]. PABA, which
can diffuse across biological membranes [18], rescued
bacterial growth at nanomolar concentrations independ-
ently of abgT expression (Fig. 3). Overall, restoration of
bacterial growth by folic acid can be largely explained by
PABA-glu uptake by AbgT, while low concentrations of
PABA present in folic acid preparations may explain the
ability of high concentrations of folic acid to rescue the
growth of the E. coli ΔabgT ΔpabA double mutant.
Folic acid increases E. coli folate levels in an AbgT-
dependent mechanism
In order to verify that E. coli growth following folic acid
supplementation is attributable to restored bacterial folate
synthesis, we used LC-MS/MS (see Methods) to detect
levels of individual E. coli tetrahydrofolates (THFs) under
the conditions used in the above experiment. Levels of the
most detectable, and thus likely most abundant, THF spe-
cies (5-methyl THF-glu3, 5/10-formyl THF-glu3, THF-glu3
and 5,10-methenyl THF-glu3) are presented in Fig. 4. With
supplementation of 10 μM folic acid, folate levels in ΔpabA
and ΔabgT ΔpabA were not significantly increased com-
pared to their non-supplemented controls. In contrast, in
wild-type (WT) and ΔpabA (abgT OE) strains, addition of
10 μM folic acid resulted in significantly higher levels of fo-
lates. In response to 100 μM folic acid, folate levels increased
in all strains compared to their non-supplemented controls,
where the scale of increase was dependent on abgT expres-
sion (Fig. 4). At 100 μM folic acid, folate levels were highest
in ΔpabA (abgT OE) followed by WT, ΔpabA, and finally
lowest in the ΔabgT ΔpabA double mutant (Fig. 4). The
a b c
Fig. 3 Folic acid supplement breakdown supports E. coli growth. Bacterial lawn growth, under PABA-depleted conditions, of E. coli WT, ΔpabA,
ΔabgT ΔpabA and ΔpabA (abgT OE) on DM plates supplemented with (a) folic acid, (b) PABA-glu and (c) PABA as measured by OD600 after
4 days growth at 25 °C (see Methods). Each data point is the average of 8 plates. Error bars represent standard deviation. Asterisks denote the
test statistic from Student’s t test comparison of means, where ***p < 0.001, **p < 0.01,*p < 0.05 compared to ΔpabA growth on the
comparable condition
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abgT genotype had a strong effect on the folate levels of the
ΔpabA strains at 100 μM folic acid (Fig. 4, pair-wise com-
parisons between ΔpabA and the ΔabgT ΔpabA and ΔpabA
(abgT OE) strains are indicated by crosses). In summary,
folic acid supplementation was found to increase E. coli
folate levels in an abgT-dependent mechanism.
Folic acid preparations contain PABA-glu and PABA
Together, the data presented here indicate that the main
route of C. elegans folic acid supplementation is indirect
via E. coli uptake of PABA-glu and PABA. We used
LC-MS/MS to test for the presence of these breakdown
products in folic acid preparations from Schircks (used
in all other experiments in this study), Sigma Aldrich,
and Boots, a UK retailer of supplements. We also tested
for further folic acid breakdown under the experimental
conditions used here by analysing extracts from agar
media supplemented with Schircks folic acid and incu-
bated at 25 °C for 4 days. We detected PABA-glu in all
three folic acid sources at between 0.3% (Schircks) and 4%
(Boots, Fig. 5). Under the conditions used for C. elegans
experiments, PABA-glu increased to 1.18%, suggesting
further breakdown. PABA was found at between 0.01%
(Schircks) and 0.06% (Boots, Fig. 5); this level of PABA in
folic acid preparations may explain why folic acid can
increase folates in a ΔabgT ΔpabA double mutant.
Folic acid shortens C. elegans lifespan via AbgT-
dependent uptake of PABA-glu
Inhibiting bacterial folate synthesis, without affecting
bacterial growth, is known to increase C. elegans life-
span [12, 13]. It was therefore hypothesized that, if
folic acid increased bacterial folate synthesis, it may
shorten C. elegans lifespan under conditions where
bacterial folate synthesis was inhibited. Consistent
with our previous findings [13], we find that C. ele-
gans maintained on any E. coli ΔpabA mutant are
long-lived compared to C. elegans fed WT E. coli
(Fig. 6, Additional file 1: Table S1), whereas the
ΔabgT mutation alone had no impact on C. elegans life-
span (p = 0.4312, Additional file 2: Figure S1b). Further,
10 μM folic acid was found to decrease C. elegans lifespan
on ΔpabA E. coli by 9.4% (p = 0.0052), and to decrease it
even further on ΔpabA E. coli over-expressing abgT (by
16.3%, p < 0.0001, Fig. 6a), whereas it had no effect on life-
span on the ΔabgT ΔpabA double mutant (p = 0.1901, Fig.
6a). In contrast, 100 μM folic acid decreased the lifespan
on ΔpabA E. coli by 23.9% (p < 0.0001), whereas this con-
centration only shortened the lifespan on the ΔabgT
ΔpabA double mutant by 4.7% (p = 0.0467, Fig. 6a).
Lifespans on media supplemented with PABA-glu
showed an abgT-dependent response similar to that
observed with folic acid supplementation, but at a
10-fold lower concentration (Fig. 6b). In contrast,
a c
b d
Fig. 4 Folic acid increases E. coli folate levels via uptake of PABA-glu by AbgT. Levels of (a) 5-methyl THF-glu3, (b) 5/10formyl THF-glu3, (c) THF-glu3
and (d) 5,10 methenyl THF-glu3 in extracts of E. coli WT, ΔpabA, ΔabgT ΔpabA and ΔpabA (abgT OE) mutants supplemented with 10 μM and 100 μM
folic acid. Extracts were made after 4 days of bacterial growth at 25 °C on solid agar plates. Folate counts from the LC-MS/MS were normalised by
dividing by counts of an internal MTX-glu6 spike. Error bars represent standard error of the mean of at least four replicate samples per data point (Data
in Additional file 3: Table S2). Asterisks indicate test statistic of unpaired parametric t tests with Welch’s correction, where ****p < 0.0001, ***p < 0.001,
**p < 0.01,*p < 0.05. Pairwise comparisons between ΔpabA and ΔabgT ΔpabA, ΔpabA (abgT OE) at 100 μM folic acid are indicated by †
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PABA supplementation shortened C. elegans lifespan in
all cases independently of abgT expression (Fig. 6c),
consistent with the ability of PABA to rescue E. coli
folate production in a ΔabgT ΔpabA double mutant.
Together, these results suggest that folic acid shortens
C. elegans lifespan on folate-depleted E. coli via
AbgT-dependent uptake of PABA-glu.
Discussion
In this study we have found that a major route of uptake
for the synthetic supplement folic acid by C. elegans is
via E. coli rather than directly via the worm. Why is folic
acid not taken up directly by C. elegans with the same
affinity as folinic acid? One possible explanation is that
FOLT-1, the only characterised C. elegans folate trans-
porter, is a reduced folate carrier with specificity for foli-
nic acid [17]. In humans, folic acid is also taken up in a
different manner to natural reduced folates, with the
major route thought to be via the protein-coupled folate
transporter in the small intestine [19]. A C. elegans
PCFT homologue has been identified, but its affinity for
folic acid has not been characterized [20]. In addition, a
homologue of the human folate receptor has been char-
acterised in C. elegans [21]. This study does not rule out
that direct routes for folic acid exist in C. elegans, but
indicates that they are inferior to the E. coli route.
We have found that E. coli uptake of folic acid is
dependent on its spontaneous breakdown into PABA-glu,
which can be taken up by the E. coli PABA-glu transporter,
AbgT. This transporter, which as far as we know is the only
E. coli transporter for PABA-glu, has evolved to salvage
PABA-glu from the breakdown of natural folates, and is
found in many bacteria in the human gut microbiota [22].
To our knowledge, this is the first study to show that this
bacterial gene, and its level of expression, can influence the
biology of the host, both by providing a route for folic acid
to prevent host folate deficiency (Fig. 2), but also because it
can lead folic acid to shorten the C. elegans lifespan when
worms are cultured on folate-depleted E. coli (Fig. 6). The
a
b
c
Fig. 6 Folic acid shortens C. elegans lifespan via an E. coli abgT-
dependent route during adulthood. Mean lifespan of glp-4(bn2) C.
elegans maintained from day 1 of adulthood on WT (a only), ΔpabA,
ΔabgT ΔpabA or ΔpabA (abgT OE) mutant E. coli with supplementation
of (a) folic acid, (b) PABA-glu and (c) PABA. Error bars represent
standard error. Asterisks denote the Log-rank non-parametric statistical
test of survival, where ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05,
compared to lifespan on the non-supplemented condition of the
same strain. Full lifespan data in Additional file 1: Table S1
a
b
Fig. 5 Folate preparations contain PABA-glu and PABA.
Concentrations of (a) PABA-glu and (b) PABA as determined by LC-
MS/MS in 10 and 100 μM folic acid preparations. Samples were folic
acid from Schircks, Sigma, Boots and Schircks folic acid after addition
to the agar media and incubation for 4 days at 25 °C. Error bars
represent standard deviation over triplicate independent
preparations. Full data in Additional file 4: Table S3
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increase in folate synthesis caused by folic acid supplemen-
tation leads to a bacterial activity/toxicity that is harmful to
the worm over the long term [13] (Fig. 7).
It is possible that this bacterial route for folic acid ex-
ists in humans. As far as we are aware, no other studies
have tested folic acid supplements for the presence of
PABA-glu or PABA, but several studies have reported is-
sues with the stability and dissolution of commercial
folic acid supplements [23, 24]. In light of these issues,
manufacturers have adopted a policy of ‘overages’ in
order to ensure sufficient folic acid is released in the
small intestine following ingestion [25]. The presence of
PABA-glu and PABA in a commercially available folic
acid source (Fig. 6), combined with the instability of folic
acid at the low pH conditions of the stomach [26–28],
makes it likely that PABA-glu and PABA will be avail-
able to the gut microbiota following supplementation.
PABA has been identified as a human faecal excretory
product after ingestion of folic acid [29]. Furthermore,
studies in rodents [30] and piglets [31] have demon-
strated that infusion of labelled PABA into the cecum
results in the incorporation of bacterially synthesized
folate in host tissues. Thus, the literature suggests that
the components for such a route exist in humans, but
the importance of this route is yet to be determined. We
detected this route in C. elegans because of the poor bio-
availability of folic acid in our folate deficiency model.
Folic acid is taken up well by humans and leads to in-
creases in serum folate levels, but circulating folic acid is
often found to have retained its oxidised form, suggest-
ing that it is not always bioavailable even when absorbed
by the host [3, 8, 32]. The bacterial route increases
bioavailability.
Further studies are required in order to determine
whether folic acid supplementation affects the folate status
of human gut microbes and whether this in turn impacts
host health. Interestingly, there are several diseases associ-
ated with an increased abundance of folate-synthesizing
gut bacteria, such as inflammatory bowel disease [33] and
small intestinal bacterial overgrowth [34], but a causal re-
lationship between bacterial folate and disease has not
been established. The abgT gene is found in the genomes
of several enteric pathogens, including Enterobacter clo-
acae, Neisseria gonorrhoeae, Salmonella enterica, Shigella
boydii and Staphylococcus aureus, in addition to E. coli.
Whilst there is much consideration about the conse-
quences of folic acid supplementation [3, 9, 10], our work
here indicates that folic acid supplement instability and
bacterial metabolism are previously unexplored variables
that may impact human health and thus warrant consider-
ation in future reports and studies.
Conclusions
The main route of uptake of the synthetic supplement
folic acid by C. elegans is via E. coli, with a dependence on
breakdown of folic acid. Folic acid supplements contain
breakdown products, raising the possibility that this route
could occur in humans. This route shortens the lifespan
of C. elegans on folate-depleted E. coli, suggesting that
there are circumstances in which this bacterial route could
have negative consequences for human health.
Methods
Folates and related compounds
Folic acid, folinic acid, PABA-Glu, 5-formylTHF-Glu3,
5-methylTHF-Glu3 and methotrexate-Glu6 were obtained
from Schircks, Switzerland. PABA, vitamin B12 and folic
acid were purchased from Sigma Aldrich and folic acid
supplement from Boots, UK.
Fig. 7 Schematic of the impact of folic acid supplementation on C. elegans via indirect uptake of breakdown products by E. coli. Folic acid is not
taken up well by C. elegans directly. We find that the major uptake of folic acid by C. elegans is dependent on its breakdown into PABA-glu and
uptake by the E. coli AbgT transporter. This route increases bacterial folate synthesis in both WT and ΔpabA mutant E. coli. Under conditions of
folate deficiency (ΔpabA mutant E. coli), increasing bacterial folate via this route is beneficial for C. elegans development. During C. elegans
adulthood, this route has a negative impact on longevity as it promotes a bacterial folate-dependent toxicity
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Culture conditions
DM was prepared as previously described [13], except
that 10 nM vitamin B12 was added. Vitamin B12, folic
acid and antibiotics were added post-autoclaving for
agar plates. DM for liquid culture was filter sterilised.
Following addition of 0.1 μM PABA to the liquid DM
media, this was used to seed the plates in order to
maintain bacterial growth (apart from growth experi-
ments in Fig. 2). Then, 30 μL of 3 mL fresh overnight
LB culture were used to inoculate 5 mL of DM (in 15 mL
Falcon tubes). Kanamycin (25 μg/mL and 50 μg/mL of
ampicillin if necessary) were added to both LB and DM
pre-incubation. DM liquid cultures were incubated for
18 h at 37 °C and 220 RPM.
All strains were derived from the Keio collection [35]
(Table 1). The ΔabgT ΔpabA double mutant was made
using the P1 transduction protocol as described in [36].
The abgT over-expression plasmid (pJ128) [16] and
empty vector (puc19) [37] were transformed into appro-
priate strains.
C. elegans strains used
SS104 glp-4(bn2), UF208 (WT) and UF209 gc
p-2.1(ok1004) [13].
E. coli preparation and growth assay
E. coli was prepared as follows for all E. coli and C. ele-
gans experiments. A 30 μL aliquot of an overnight LB
culture of E. coli was transferred into 5 mL of DM and
incubated for 18 h at 37 °C and 220 RPM. Then, 100 μL
of the DM culture was seeded onto DM agar plates and
incubated at 25 °C for 4 days. E. coli was removed by
pipetting 1 mL of M9 medium onto the plate and a glass
spreader was used to scrape off the bacterial lawn. The
bacterial suspension was pipetted into a 1.5 mL Eppen-
dorf and the volume was recorded (v). Tubes were
vortexed vigorously to obtain a homogenised solution.
Finally, 100 μL were taken and diluted with 900 μL of M9
in a cuvette. A spectrophotometer was used to read bac-
terial growth at 600 nm. Bacterial growth was calculated
by multiplying OD600 by the volume of the sample (v).
E. coli folate extraction
Bacterial lawns were scraped from plates into microcen-
trifuge tubes using M9 solution and kept on ice. Volume
(v) multiplied by the OD600 of the solution (diluted 1:5)
gives a measure of the amount of material. Samples were
concentrated in a cooled microcentrifuge and pellets
were snap frozen in liquid nitrogen. Pellets were thawed
and resuspended in a volume of ice-cold 90% methanol:
10% folate extraction buffer (FEB: 50 mM HEPES,
50 mM CHES, 0.5% w/v ascorbic acid, 0.2 M DTT,
pH 7.85 with NaOH) in proportion to bacterial content
(37.5 × OD600 × v). FEB was spiked with 10 nM
methotrexate-Glu6 as an internal standard. Samples were
vortexed vigorously and left on ice for 15 min before
centrifugation in a cooled microcentrifuge for 15 min at
full speed. Supernatants were used for analysis.
Folate LC-MS/MS analysis
Folates were detected by multiple reaction monitoring
(MRM) analysis using a SCIEX QTRAP 6500 instrument.
MRM conditions for folic acid, PABA, PABA-Glu,
5-Me-H4PteGlu3 (5-methylTHF-Glu3) and 5/10-CHO-H4P-
teGlu
3
(formyl THF3) were optimised by infusion of
standards into the instrument. The optimised condi-
tions for –Glu3 folates were applied to other higher
folates using MRM transitions as described by Lu et al.
[38]. Further confirmation of identity for folates of
interest was achieved by performing enhanced product
ion scans and comparing the fragment spectra with
known standards.
The QTRAP 6500 was operated in ESI+ mode and
was interfaced with a Shimadzu Nexera UHPLC system.
Samples were separated using a Thermo PA2 C18
column (2.2 μm, 2.1 × 100 mm) with a gradient of 0.1%
Table 1 E. coli strains used in this study
Strain Genotype Plasmid Characteristics Source
BW25113/pGreen 0029 WT pGreen 0029 kanr Virk et al. 2016 [13]
JW3323-1 ΔpabA n/a kanr Baba et al. 2006 [25]
JW5822-1 ΔabgT n/a kanr Baba et al. 2006 [25]
CMabgTpabA ΔabgT ΔpabA n/a kanr This study
CM1 WT pUC19, pGreen 0029 kanr, ampr This study
CM2 ΔpabA pUC19 kanr, ampr This study
CM3 ΔabgT ΔpabA pUC19 kanr, ampr This study
CM4 WT (abgT OE) pJ128, pGreen 0029 kanr, ampr This study
CM5 ΔpabA (abgT OE) pJ128 kanr, ampr This study
CM6 ΔabgT ΔpabA (abgT OE) pJ128 kanr, ampr This study
r= resistance
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formic acid in water (mobile phase A) and acetonitrile
(mobile phase B). Samples were maintained at 4 °C and
2 μL aliquots were injected. The column was maintained
at 40 °C with a flow rate of 200 μL/min, starting at 2%
B, held for 2 min, with a linear gradient to 100% B at
7 min, held for 1 min, before a 7 min re-equilibration
step at 2% B necessary for consistent retention times.
The column eluate flow to the MS was controlled via the
QTRAP switching valve, allowing analysis between 4 and
8 min to minimise instrument contamination. Folates
were quantified with reference to external standards and
matrix effects were assessed by spiking of standards into
extracted samples.
Lifespan analysis
Survival analyses were performed as described [12].
glp-4(bn2) worms were maintained at 15 °C and shifted
to 25 °C at the L3 stage. At the L4/young adult stage, an-
imals were placed on bacteria under the experimental
conditions. All lifespan data is provided in Additional file 1:
Table S1. Statistical significance was determined using Log
Rank and Wilcoxon tests of the Kaplan–Meier survival
model.
Additional files
Additional file 1: Table S1. Full analysis of lifespan conditions including
statistical analysis. (XLSX 46 kb)
Additional file 2: Figure S1. The E. coli ΔabgT deletion has no effect on
C. elegans lifespan survival curves of C. elegans glp-4(bn2) on WT E. coli and
ΔabgT mutant. See Additional file 1: Table S1 for further details. (PDF 72 kb)
Additional file 3: Table S2. Data corresponding to Fig. 4 in the main
text. (XLSX 50 kb)
Additional file 4: Table S3. Data corresponding to Fig. 5 in the main
text. (XLSX 10 kb)
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